Close Menu

AACC: Janet Kreizman

Jan 15, 2020

American Association for Clinical Chemistry CEO Janet Kreizman is retiring from the organization in the second quarter of 2020, the organization said. She has been with AACC for almost seven years. During her tenure, AACC created a first-of-its kind point-of-care testing professional certification and the launch of its second peer-reviewed journal, AACC noted. Prior to joining AACC, she was the deputy executive director and chief policy officer at the Endocrine Society, according to her LinkedIn profile. AACC's board is organizing the search process for a new CEO. 

More Like This

Aug 04, 2020

Todos Medical: Jorge Leon

Todos Medical has appointed Jorge Leon as consulting chief medical and scientific officer for infectious disease and oncology, on a part-time basis. 

In the early 1990s, he played a role in establishing the molecular diagnostics laboratories at Quest Diagnostics, Todos said. In 2003, Leon founded Leomics Associates, a consulting firm.

Todos had previously appointed Leon as a medical advisor to assist it with clinical development, regulatory strategy, and fundraising.

Jul 31, 2020

Talis Biomedical: Roger Moody, Kim Popovits, Walter Koch

Talis Biomedical has named Roger Moody as CFO, while Kim Popovits has joined the company's board and Walter Koch has joined its scientific advisory board.

Moody was formerly CFO of Clinical Genomics. He previously was chief executive and COO at Glysure and CFO of Nanosphere and Medsn. Popovits is the former chairman of the board, president, and CEO of Genomic Health, which was acquired by Exact Sciences. She also held several management positions at Genentech, now part of Roche. Koch was at Roche Molecular Systems where he held several leadership roles, including vice president and head of global research. Prior to that, he was at the US Food and Drug Administration.

Jul 29, 2020

Agendia: Brian Dow

Agendia has appointed Brian Dow as CFO. Prior to this position, he served as senior VP and CFO of Pulse Biosciences, where he was responsible for executing the company's early-stage IPO and subsequent follow-on offerings. Before that, he was CFO at Progyny, and prior to that, he was VP and principal accounting officer at Pacific Biosciences. Previously, he also worked for Ernst & Young. Dow holds a bachelor's degree from Georgia Institute of Technology.

Jul 28, 2020

Aegea Biotechnologies: George Maltzeos

Aegea Biotechnologies said that it has hired George Maltzeos as chief engineer to help expedite the development of the company's point-of-care lateral flow molecular SARS-CoV-2 test being developed in collaboration with Tauriga Sciences. Maltzeos previously served as director of the California Institute of Technology Global Health Initiative where he helped secure $4.5 million in funding from the Bill & Melinda Gates Foundation to develop point-of-care clinical diagnostics for developing countries. He also previously founded and served as chief engineer for Helixis, which was acquired by Illumina in 2010. Maltzeos holds a PhD in electrical engineering from CalTech and a BS from Columbia University.

Jul 28, 2020

Clinical Genomics: Michael Paris, Zivjena Vucetic, Edward Rosen

Clinical Genomics has appointed Michael Paris as chief operating officer, Zivjena Vucetic as senior VP, medical, and Edward Rosen as chief strategy and commercial officer.

Paris most recently served as COO and senior VP, operations and technology development, at Origin. Prior to Origin, he served in several positions at Bioconnect Systems, Orthovita, and Rex Medical. 

Before Clinical Genomics, Vucetic served as medical director at Ortho-Clinical Diagnostics. Prior to that, she held multiple scientific and medical roles at Fujirebio Diagnostics. 

Rosen most recently served as an executive in residence at Columbia University. Prior to Columbia, he held several research roles at Johnson & Johnson. 

Jul 28, 2020

Meridian Bioscience: Anthony Bihl

Meridian Bioscience announced the appointment of Anthony Bihl to its board of directors, effective immediately. Bihl retired in April as CEO of Bioventus and was previously the CEO of American Medical Systems and CEO of Siemens Medical Solutions Diagnostics. He has also served in senior executive roles at Bayer Healthcare's diagnostics division and in multiple operations and finance roles at Dupont.

Jul 27, 2020

Veracyte: Jens Holstein, James Erlinger

Veracyte has appointed Jens Holstein to its board of directors and James Erlinger as executive VP, general counsel, and secretary.

Holstein was appointed as CFO of MorphoSys in 2011. Prior to MorphoSys, he served as regional CFO of the Europe/Middle East region for Fresensius Kabi, a subsidiary of Fresenius. He has also held several other leadership roles within the Fresenius group. 

Erlinger previously served as executive VP, general counsel, and secretary of Iqvia. He spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner. 

Jul 24, 2020

Cradle Genomics: Tanya Moreno, Sue Gross

Prenatal diagnostics firm Cradle Genomics has appointed Tanya Moreno as VP of development and Sue Gross as chief medical officer.

Moreno has 13 years of experience in diagnostics development and the commercialization of genomic tests. She holds a PhD in molecular genetics and developmental biology from the California Institute of Technology.

Gross joins the company from Sema4, where she was medical director for the reproductive lab and clinical analysis division. Previously, she was chief medical officer at Natera, and before that, professor of obstetrics and gynecology, pediatrics, and genetics at Montefiore Einstein. She is a physician with board certifications in obstetrics and gynecology as well as medical genetics.

Jul 23, 2020

Quotient: Isabelle Buckle, Catherine Larue

Quotient announced the appointment of two new members to its board of directors to replace Sarah O'Connor and Thomas Bologna, who are stepping down. Isabelle Buckle is the executive VP of technology transfer and industrial partnership at the Institut Pasteur in Paris. She was previously the global VP of clinical mass spectrometry at Bruker Daltonics and CEO and chairman of InGen Biosciences. 

Catherine Larue is the director of external affairs at the Integrated Biobank of Luxemburg and formerly served as CEO at the biobank. She previously led a business unit at Bio-Rad Laboratories. Both Buckle and Larue will join the board on Sept. 1. 

Jul 22, 2020

Myriad Genetics: Walter Gilbert, Daniel Skovronsky

Myriad Genetics has expanded its board of directors to 10 members with the election of Daniel Skovronsky, CSO and president of Lilly Research Laboratories at Eli Lilly. Skovronsky will serve on the research and product innovation committee within Myriad’s board. Additionally, Myriad announced that Walter Gilbert, the director and vice chair of the board, will retire from these positions at the firm's annual stockholder meeting in December. Gilbert cofounded Myriad and received a Nobel Prize in chemistry in 1980 for his development of rapid DNA sequencing technology. 

Jul 22, 2020

Biodesix: Jean Franchi, Hany Massarany

Biodesix has appointed Jean Franchi and Hany Massarany to its board of directors. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing.

Franchi currently serves as chief financial officer for Replimune Group, a biotechnology company developing oncolytic immuno-gene therapies. She has led operational and financial strategy at several companies in domestic and international markets of various stages and sizes, including 16 years at Genzyme. She holds a bachelor's degree in business administration from Hofstra University.

Massarany served as president and chief executive officer of GenMark Diagnostics from 2011 to 2020. Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics. From 1999 to 2009 he was responsible for various global leadership positions with Ventana. He has also held executive management positions with Bayer Diagnostics and Chiron Diagnostics. Massarany earned a bachelor’s degree in microbiology and immunology from Monash University and an MBA from Melbourne University.

Jul 20, 2020

Todos Medical: Priyanka Misra, Elise Brownell

Todos Medical has appointed Priyanka Misra VP of corporate development and Elise Brownell VP of R&D. Misra previously was a senior investment analyst at Feller Advisors. Prior to that, she was at Goldman Sachs Asset Management in the Alternative Investments and Manager Selection group. Brownell started her career at the State University of New York, Stony Brook before moving to Frederick Cancer Research Facility and Bayer Healthcare.

Jul 20, 2020

NeoGenomics:  Michael Kelly, Lynn Tetrault

NeoGenomics said Michael Kelly has joined its board of directors and Lynn Tetrault has been named lead independent director of the board.

Kelly joined the board on July 15 and will serve as a member of the audit committee. He is a former senior executive of Amgen and is currently acting as founder and president of Sentry Hill Partners. He has served in various strategic finance and operations positions at Amgen, most recently as senior vice president of global business services and VP and CFO of international commercial operations. Kelly has also held positions at Biogen, Tanox, and Monsanto Life Sciences.

Tetrault also assumed her new role as of July 15. She has served on the company’s board since June 2015 and is chair of the compensation committee. She founded Anahata Leadership, an advisory firm focused on supporting the leadership effectiveness of executive women. She worked from 1993 to 2014 with AstraZeneca, most recently on its global executive team as executive vice president of human resources and corporate affairs from 2007 to 2014. Prior to AstraZeneca, Tetrault practiced healthcare and corporate law at Choate, Hall and Stewart in Boston.

Jul 14, 2020

Pattern Bioscience: Nick Naclerio

Nick Naclerio is joining Pattern Bioscience's board of directors in conjunction with the company's recent Series B-1 funding round. He is a founding partner of Illumina Ventures and the former senior VP of corporate and venture development at Illumina.

Jun 24, 2020

Sera Prognostics: Thomas Garite

Sera Prognostics has appointed Thomas Garite its vice president of clinical sciences. He will work to advance the Salt Lake City-based firm's clinical development programs as Sera Prognostics moves into the commercial stage. Garite recently retired as the Edward H. Quilligan Professor of Obstetrics and Gynecology at the University of California, Irvine. He was the department's chairman for 18 years and is now professor emeritus. He also served as director of research and education for obstetrix at the MedNax Medical Group. He currently is chief clinical officer for patient safety company Perigen.